MORF-627 is a selective, orally active inhibitor for integrin αvβ6 with an IC 50 of 9.2 nM measuring by human serum ligand binding assay. MORF-627 inhibits αvβ6-mediated TGF-β1 activation with an IC 50 of 2.63 nM, inhibits SMAD2/3 phosphorylation with an IC 50 of 8.3 nM. MORF-627 ameliorates the Bleomycin -induced mouse lung fibrosis.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.